Hinfact

EVerZom is a nanomedicine biotech company providing a large scale of GMP manufacturing platform of extracellular vesicles. They develop a bioproduction platform to produce extracellular vesicles at a commercial scale in a GMP compliant way for pharmaceutical companies with applications in regenerative medicine and drug delivery. Extracellular vesicles that encompass exosomes, microvesicles, and apoptotic bodies are the tools used by cells to communicate with each other. EVerZom was founded in 2019 and is headquartered in Paris, Ile-de-France, France.

SeaBeLife is a biotech firm creating various drug options designed to inhibit regulated necrosis in cells using patented molecules.

Genoskin is a biotech company that leverages its expertise in skin biology and immunology to enhance the development of medications.

The International Energy Agency predicts that meeting the goals of the Paris Agreement will require significantly increased mineral requirements for clean energy technologies by 2040. Transitioning to net-zero globally by 2050 would necessitate even higher mineral inputs. This shift towards clean energy will involve intense mining of critical metals such as Cobalt, Nickel, and Lithium, leading to various environmental and social issues. The current imbalance in critical metal supply and demand presents challenges for achieving carbon neutrality goals. Companies are exploring alternative methods for sourcing critical metals, including deep-sea mining and asteroid mining, but these come with significant risks and obstacles. Genomines is taking a unique approach by using genetically modified plants to extract metals from soils in a sustainable and environmentally friendly manner. Despite the challenges, efforts are being made to make green energy more sustainable while addressing the increasing demand for critical metals.

Osivax develops immunotherapy vaccines that aim to simplify the treatment of contagious illnesses. These vaccines enhance the absorption into dendritic cells and enhance the immune response to natural proteins, resulting in a more powerful and unique activation of CD8 T cells. By doing so, doctors can effectively treat patients with cancer, as well as influenza, malaria, and other infectious diseases in a more efficient manner.

MaaT Pharma, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating a range of cancers and Graft-versus-Host-Disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into improving outcomes of immunotherapy in solid tumors, we have built a powerful discovery and analysis platform, GutPrint®, to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions.

One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline Vallot to use single-cell technologies to discover innovative treatments for challenging medical conditions.

GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases. Based on recent results obtained by the teams of its scientific founders, the company develops innovative approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness.

AB Science was established in 2001 by a group of individuals in the medical and business fields who are committed to finding important mechanisms in life science and creating innovative drugs that can greatly improve the lives of patients with significant medical needs. These individuals are pioneers and leaders in the life science industry.

bYoRNA is a French biotechnology company specializing in the cost-efficient, scalable bioproduction of high-quality therapeutic messenger RNA (mRNA) using engineered eukaryotic cells, particularly recombinant yeast. Their disruptive platform enables the production of long, humanized mRNA with lower immunogenicity and higher integrity compared to traditional in vitro enzymatic synthesis. This technology aims to mass produce mRNA for gene therapies, cancer vaccines, and infectious disease vaccines at a fraction of current costs, making mRNA therapeutics more accessible globally.

AFYREN is a biotech company dedicated to developing innovative biobased solutions for high value-added compounds with the goal of enabling a low-carbon, circular industry. Our technology is based on a patented biomimetic fermentation process and our production model at our first plant, AFYREN NEOXY, produces 100% biobased acids in a low-carbon, zero-waste biorefinery in France. We work with partners in various industries to create sustainable products that meet market demands, while prioritizing sustainability and minimizing our environmental impact. Join us in our mission to revolutionize the chemical industry through bioeconomy and sustainable innovation!

Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small molecule treatments for patients with serious medical needs in fibrosis, lysosomal storage disorders, and oncology. They have developed a pipeline supported by a discovery engine containing a large collection of unique molecules, a research and development facility that they own entirely, and a team with extensive experience in developing compounds targeting nuclear receptors, transcription factors, and epigenetic modulation. By utilizing these assets and expertise, they are progressing two clinical candidates across three indications, in addition to a number of early-stage programs in their pipeline.